国家卫健委：对个别违背医德、损害公共利益、患者权利的医务人员“零容忍”

Core Viewpoint - The joint announcement by 14 ministries aims to strengthen the governance of the pharmaceutical and medical service sectors, focusing on preventing corruption and ensuring compliance within the industry [1][2][3]. Group 1: Governance and Compliance - Continuous efforts are required to consolidate the achievements in the governance of the pharmaceutical procurement and sales sector, with a focus on preventing the resurgence of corruption [1]. - The establishment of a credit system in the pharmaceutical distribution industry is emphasized, along with the implementation of a "blacklist" system for bribers and corrupt entities [2]. - The announcement encourages pharmaceutical companies to enhance compliance management by referring to guidelines aimed at preventing commercial bribery [1][2]. Group 2: Regulatory Measures - The document outlines the need for a comprehensive audit and supervision mechanism that covers the entire process from raw material procurement to drug production and distribution [1]. - Specific measures to regulate internet medical practices are highlighted, including the need for consistent qualifications and activities between online and physical medical institutions [2]. - A multi-departmental collaborative mechanism is proposed to address illegal activities in the medical internet space, such as fraudulent advertising and unauthorized marketing practices [2]. Group 3: Ethical Standards and Patient Protection - The responsibility of medical institutions in managing medical ethics is reinforced, with a zero-tolerance policy for violations that harm public interests and patient rights [3]. - The safety of medical insurance funds is prioritized, with strict measures against fraud and misuse of funds, ensuring accountability at the individual level [3]. - The announcement calls for the optimization of centralized procurement platforms for drugs and high-value medical consumables to enhance quality and efficiency [3].